DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

We recently compiled a list of the 15 Best S&P 500 Dividend Stocks to Buy Now. In this article, we are going to take a look ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

This was the stock's third consecutive day of gains.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...